After recent approvals of pralsetinib in patients with RET-altered NSCLC and thyroid cancers and respective publications of these data, here we present interim data on the efficacy and safety of pralsetinib in prospectively identified patients with diverse RET fusion–positive tumors. Here, RET is linked to thyroid gland carcinoma.